publication date: Apr. 30, 2015

NCI CTEP-Approved Trials for the Month of April


The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase II

A011203: A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer. Alliance for Clinical Trials in Oncology; Goetz, Matthew P. (507) 284-4857


EA8141: A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. ECOG-ACRIN Cancer Research Group; Margulis, Vitaly. (214) 648-0567


NRG-GY001: A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum. NRG Oncology; Farley, John Hall. (602) 406-7730


NRG-GY002: A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer. NRG Oncology; Santin, Alessandro D. (203) 785-6301


Phase II/III

Continue reading CCL April – NCI CTEP-Approved Trials for the Month of April

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.